Compare Citius Pharmaceuticals Inc (CTXR) vs Otis Worldwide Corp (OTIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Otis Worldwide Corp — how do they compare? Citius Pharmaceuticals Inc trades at $0.54 (market cap $14.64M), while Otis Worldwide Corp trades at $71.64 (market cap $27.84B). The key difference: Otis Worldwide Corp is far larger — about 1901.6× Citius Pharmaceuticals Inc's market cap, and Otis Worldwide Corp pays a 2.34% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | OTIS | |
|---|---|---|
Market Cap | $14.64M | $27.84B |
Sector | Health | Industrials |
52-Week High | $1.82 | $101.07 |
52-Week Low | $0.53 | $69.34 |
Enterprise Value | $10.86M | $35.23B |
Dividend Yield | — | 2.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
Otis Worldwide trades at $73.42, up 0.45% today, with a bullish technical signal from moving averages but mixed quarterly earnings. The company maintains stable revenue near $14.4B (2025) and a net margin of 10.11%, supported by service growth and modernization initiatives like recent upgrades at Christ the Redeemer in Brazil. Cash flow from operations remains strong at $1.6B, though net cash flow turned negative in 2025 due to financing activities.
The stock offers 24% upside to the consensus price target of $91.00, with analysts divided (38% Buy, 54% Hold). Risks include debt levels (75.54% debt-to-asset ratio) and margin pressure from tariffs, but dividend growth (5% increase to $0.44) and buybacks provide shareholder value. Near-term performance hinges on Q2 2026 earnings due July 22, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →
